Revolutionizing Cancer Treatment: Unveiling the Power of CAR T-cell Therapy.

IF 2.6 4区 医学 Q2 PHARMACOLOGY & PHARMACY Current pharmaceutical design Pub Date : 2025-01-02 DOI:10.2174/0113816128336391241107112957
Amir Hossein Barjasteh, Mostafa Saebi, Mahmoud Mahmoudi, Ramiar Kamal Kheder, Seyed Isaac Hashemy, Fatemeh Forouzanfar, Seyed-Alireza Esmaeili
{"title":"Revolutionizing Cancer Treatment: Unveiling the Power of CAR T-cell Therapy.","authors":"Amir Hossein Barjasteh, Mostafa Saebi, Mahmoud Mahmoudi, Ramiar Kamal Kheder, Seyed Isaac Hashemy, Fatemeh Forouzanfar, Seyed-Alireza Esmaeili","doi":"10.2174/0113816128336391241107112957","DOIUrl":null,"url":null,"abstract":"<p><p>Cancer is a significant health challenge worldwide, causing social and economic burdens. Despite advancements in medicine, it remains a leading cause of death and is projected to increase by 2040. While conventional treatments like surgery, radiation, and chemotherapy are effective, they often have severe side effects. CAR T-cell (chimeric antigen receptor T-cell) treatment is a novel immunotherapy method personalized to the patient's immune system and directly targets cancer cells. It originated in the 1980s, and advancements have made it more effective. However, challenges remain, such as severe side effects, high costs, and manufacturing variability. Despite these challenges, the treatment with CAR T-cells has shown remarkable success, especially in hematologic malignancies. Though it is new to solid tumours, ongoing research looks promising. CAR T-cell therapy offers hope for fightingcancer, and it stands poised to redefine cancer treatment paradigms, giving renewed optimism to patients globally.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pharmaceutical design","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113816128336391241107112957","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Cancer is a significant health challenge worldwide, causing social and economic burdens. Despite advancements in medicine, it remains a leading cause of death and is projected to increase by 2040. While conventional treatments like surgery, radiation, and chemotherapy are effective, they often have severe side effects. CAR T-cell (chimeric antigen receptor T-cell) treatment is a novel immunotherapy method personalized to the patient's immune system and directly targets cancer cells. It originated in the 1980s, and advancements have made it more effective. However, challenges remain, such as severe side effects, high costs, and manufacturing variability. Despite these challenges, the treatment with CAR T-cells has shown remarkable success, especially in hematologic malignancies. Though it is new to solid tumours, ongoing research looks promising. CAR T-cell therapy offers hope for fightingcancer, and it stands poised to redefine cancer treatment paradigms, giving renewed optimism to patients globally.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
革命性的癌症治疗:揭示CAR - t细胞疗法的力量。
癌症是世界范围内的一项重大健康挑战,造成社会和经济负担。尽管医学取得了进步,但它仍然是导致死亡的主要原因,预计到2040年还会增加。虽然手术、放疗和化疗等传统治疗方法有效,但它们往往有严重的副作用。CAR - t细胞(嵌合抗原受体t细胞)治疗是一种针对患者免疫系统的个性化免疫治疗方法,直接针对癌细胞。它起源于20世纪80年代,随着技术的进步,它变得更加有效。然而,挑战仍然存在,例如严重的副作用、高成本和制造可变性。尽管存在这些挑战,CAR - t细胞治疗已经显示出显著的成功,特别是在血液系统恶性肿瘤中。虽然它对实体肿瘤来说是新的,但正在进行的研究看起来很有希望。CAR - t细胞疗法为对抗癌症带来了希望,它将重新定义癌症治疗模式,给全球患者带来新的乐观情绪。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.30
自引率
0.00%
发文量
302
审稿时长
2 months
期刊介绍: Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field. Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.
期刊最新文献
Fabrication of Mastic Gum Resin Tethered Phospholipid Nanocarriers for the Evaluation and Enhancement of Anti-inflammatory and Anti-bacterial Effects. Advancements in Managing Schizophrenia through Classical Approaches, Mechanisms, and Deep Brain Stimulation. Mesenchymal Stem Cell-conditioned Medium Attenuated CoCl2-induced Injury of Renal Tubular Epithelial Cells by Inhibiting NCOA1, HIF-1α, and Sox9. 3',4'-Dihydroxy Flavonol (DiOHF) Exerting a Positive Effect on Neurogenesis and Retinal Damage in Experimental Brain Ischemia-Reperfusion of Rats. Crosstalk: Biochemical Signatures and Clinical Implications in Rare Hereditary Hemolytic Anemias (Hereditary Spherocytosis).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1